Search

Your search keyword '"Choueiri T"' showing total 335 results

Search Constraints

Start Over You searched for: Author "Choueiri T" Remove constraint Author: "Choueiri T"
335 results on '"Choueiri T"'

Search Results

2. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

3. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

4. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

5. Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial

8. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study

9. Role of prior nephrectomy for synchronous metastatic Renal Cell Carcinoma (mRCC) on efficacy in patients treated with Avelumab + Axitinib (A + Ax) or Sunitinib (S): Results from JAVELIN Renal 101

10. The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective

11. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.

14. Survie conditionnelle et suivi à 5 ans dans l’étude checkmate 214 : Nivolumab + Ipilimumab (N+I) versus Sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (ACCR)

15. Nivolumab + Cabozantinib (N+C) vs Sunitinib (S) en première ligne (1L) de traitement chez des patients atteints d’un carcinome rénal avancé (ACCR) dans l’essai de phase III checkmate 9ER : analyse en sous-groupes basée sur l’absence ou présence de néphrectomie antérieure

16. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†

18. Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design

20. CheckMate-9ER-Studie: Nivolumab + Cabozantinib im Vergleich zu Sunitinib bei fortgeschrittenem Nierenzellkarzinom - aktualisierte Ergebnisse mit verlängerter Nachbeobachtung und bei sarkomatoider Histologie

22. Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC) : Effect of subsequent therapy on survival outcomes in the lenvatinib (L) plus everolimus (E) vs sunitinib (S) treatment arms

23. CheckMate-9ER-Studie: Nivolumab + Cabozantinib im Vergleich zu Sunitinib bei fortgeschrittenem Nierenzellkarzinom - aktualisierte Ergebnisse mit verlängerter Nachbeobachtung und bei sarkomatoider Histologie

24. O12 - Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial

28. METEOR Studie: Analyse des Gesamtüberlebens (OS) basierend auf der frühen Tumorvolumenreduktion (eTS) in der Phase III Studie von Cabozantinib (Cabo) versus Everolimus (Eve) beim fortgeschrittenen Nierenzellkarzinom (RCC)

29. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

36. Nivolumab + ipilimumab (N + I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés

37. Lebensqualität-adaptierte Zeit ohne Symptome oder Toxizität (Q-TWiST): Analyse von Cabozantinib (C) gegenüber Sunitinib (S) bei Patienten mit fortgeschrittenem Nierenzellkarzinom (aRCC) und intermediärem/hohem Risiko (Allianz A031203)

38. Erratum: The Immune Landscape of Cancer (Immunity (2018) 48(4) (812–830.e14), (S1074761318301213), (10.1016/j.immuni.2018.03.023))

42. Refractory renal cell cancer (RCC) exhibits high adenosine A2A receptor (A2AR) expression and prolonged survival following treatment with the A2AR antagonist, CPI-444.

44. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

45. METEOR Studie: Retrospektive Analyse von Patienten mit fortgeschrittenem Nierenzellkarzinom bezüglich der Wirksamkeit von Cabozantinib (CABO) vs Everolimus (EVE) in Abhängigkeit vom Nephrektomiestatus

46. Three-Year Efficacy and Safety Update From the Phase III Checkmate 025 Study of Nivolumab (NIVO) v Everolimus (EVE) in Patients With Advanced Renal Cell Carcinoma (aRCC)

Catalog

Books, media, physical & digital resources